Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Fulgent Genetics ( (FLGT) ).
On May 15, 2025, Fulgent Genetics held its Annual Meeting of Stockholders, where approximately 82% of eligible shares were represented. Key decisions included the election of directors, ratification of Deloitte & Touche LLP as the independent auditor, and approval of executive compensation, reflecting the company’s ongoing governance and operational strategies.
The most recent analyst rating on (FLGT) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Fulgent Genetics scores moderately due to financial challenges and valuation concerns, despite a robust balance sheet and positive momentum in certain technical indicators. The earnings call provided optimism with strong growth figures and strategic initiatives, but operational inefficiencies and cash flow issues need addressing for a more favorable outlook.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. operates in the genetics industry, focusing on providing comprehensive genetic testing services. The company is known for its advanced technology in genetic sequencing and diagnostics, catering to a wide range of healthcare needs.
Average Trading Volume: 503,356
Technical Sentiment Signal: Hold
Current Market Cap: $617.7M
For an in-depth examination of FLGT stock, go to TipRanks’ Stock Analysis page.